Security key
156944100
CG Oncology, Inc. - Common Stock, par value $0.0001 (CGON)
CUSIP: 156944100
Q4 2024 13F Holders as of 31 Dec 2024
- Security type / class
- Equity / Common Stock, par value $0.0001
- Total 13F shares
- 66,057,386
- Total 13F value
- $1,894,540,823
- Share change
- +10,750,244
- Put/Call ratio
- 17%
- SEC-reported price per share
- $28.68
- Number of holders
- 137
- Value change
- +$282,964,154
- Number of buys
- 86
- Number of sells
- 43
- Shares outstanding
- 87,881,102
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
137
Top holders
10
CGON full security history
Ownership snapshot
Full 13F holder table
CG Oncology, Inc. SEC filings
CG Oncology, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of CGON - CG Oncology, Inc. - Common Stock, par value $0.0001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Decheng Capital Global Li...
Disclosed value leader
Decheng Capital LLC
Comparable rows
15/15
Latest evidence
31 Dec 2024
13D/G
3/4/5
13F
Lead comparable stake: 8.4%
13D/G row: Decheng Capital Global Life Sciences Fund IV, L.P.
Showing 1-6 of 15 holder rows.
Quick read
Decheng Capital Global Life Sciences Fund IV, L.P. leads the comparable SEC ownership view at 8.4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Decheng Capital Global Life Sciences Fund IV, L.P.'s linked filing trail.
Comparable ownership
Top 5
Decheng Capital Global Life Scien...
8.4%
Unique Diamond Investments Ltd
5.5%
Decheng Capital LLC
6.2%
VANGUARD GROUP INC
5.8%
TCG Crossover Management, LLC
4.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Decheng Capital Global Life Sciences Fund IV, L.P. |
13D/G
3/4/5
Xiangmin Cui · 10%+ Owner
|
8.4%
|
$178,215,582
6,371,669 shares
|
$0 | 31 Dec 2024 |
| Unique Diamond Investments Ltd |
13D/G
SONG, Hong Fang
|
5.5%
|
$117,791,208
4,211,341 shares
|
$0 | 31 Dec 2024 |
| Decheng Capital LLC |
13F
Company
|
6.2%
|
$206,715,501
5,478,810 shares
|
— | 30 Sep 2024 |
| VANGUARD GROUP INC |
13F
Company
|
5.8%
|
$191,719,411
5,081,352 shares
|
— | 30 Sep 2024 |
| TCG Crossover Management, LLC |
13F
Company
|
4.2%
|
$138,476,872
3,670,206 shares
|
— | 30 Sep 2024 |
| BlackRock, Inc. |
13F
Company
|
4.1%
|
$134,731,074
3,570,927 shares
|
— | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
137
Shares
66,057,386
Rows available
137
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
120
Q4 2024 holders
137
Holder diff
17
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|